Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Rapport Therapeutics, Inc.RAPP · Entity 4394 | Chief Scientific Officer | February 17, 2026 | February 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Rapport Therapeutics, Inc.
Report date February 17, 2026 · Filed February 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 393,075 |
Ending reported balance
After 2026-02-19 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-02-17 · Sale · Disposed 900 · Balance 394,675 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.39 to $28.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 2 · 2026-02-17 · Sale · Disposed 5,400 · Balance 389,275 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.40 to $29.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 3 · 2026-02-17 · Sale · Disposed 2,200 · Balance 387,075 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.45 to $29.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 4 · 2026-02-19 · Exercise / conversion · Acquired 6,000 · Balance 393,075 F5: Transaction involved a cash exercise of options to purchase shares of the Issuer's common stock. No shares of the Issuer's common stock were sold as part of this transaction. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2033-12-05 | Direct | 88,080 |
Reported balance
After 2026-02-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-19 · Exercise / conversion · Disposed 6,000 · Balance 88,080 F6: 25% of the shares underlying this option vested and became exercisable on August 7, 2024, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.39 to $28.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.40 to $29.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.45 to $29.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F5: Transaction involved a cash exercise of options to purchase shares of the Issuer's common stock. No shares of the Issuer's common stock were sold as part of this transaction.
F6: 25% of the shares underlying this option vested and became exercisable on August 7, 2024, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 19, 2026 Filed Feb 19, 2026 19:05 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | Exercise / conversionStock Options (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001193125-26-059883 · ownership.xml · derivative · entry 5 Bredt David · CIK 0002022087 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,080 Underlying: Common Stock · 6,000 shares Expires 2033-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 25% of the shares underlying this option vested and became exercisable on August 7, 2024, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 19, 2026 Filed Feb 19, 2026 19:05 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | Exercise / conversionCommon Stock | 6,000 | $1.80 | $10,800.00 |
DisclosureSEC source: 0001193125-26-059883 · ownership.xml · nonDerivative · entry 4 Bredt David · CIK 0002022087 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 393,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Transaction involved a cash exercise of options to purchase shares of the Issuer's common stock. No shares of the Issuer's common stock were sold as part of this transaction. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 19:05 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 2,200 | $29.59 | $65,107.68 |
DisclosureSEC source: 0001193125-26-059883 · ownership.xml · nonDerivative · entry 3 Bredt David · CIK 0002022087 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 387,075 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.45 to $29.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 19:05 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 5,400 | $28.95 | $156,328.38 |
DisclosureSEC source: 0001193125-26-059883 · ownership.xml · nonDerivative · entry 2 Bredt David · CIK 0002022087 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 389,275 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.40 to $29.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 19:05 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 900 | $28.02 | $25,218.99 |
DisclosureSEC source: 0001193125-26-059883 · ownership.xml · nonDerivative · entry 1 Bredt David · CIK 0002022087 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 394,675 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.39 to $28.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 16:09 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | GrantStock Option (Right to Buy) · Derivative | 103,000 | $0.00 Strike: $27.75 | $0.00 |
DisclosureSEC source: 0001193125-26-037570 · ownership.xml · derivative · entry 1 Bredt David · CIK 0002022087 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,000 Underlying: Common Stock · 103,000 shares Expires 2036-02-02 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 16:06 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 200 | $27.40 | $5,480.00 |
DisclosureSEC source: 0001193125-26-015350 · ownership.xml · nonDerivative · entry 2 Bredt David · CIK 0002022087 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 395,575 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 16:06 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 8,300 | $26.83 | $222,651.65 |
DisclosureSEC source: 0001193125-26-015350 · ownership.xml · nonDerivative · entry 1 Bredt David · CIK 0002022087 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 395,775 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.33 to $27.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 16:20 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 6,567 | $30.05 | $197,337.69 |
DisclosureSEC source: 0001193125-26-002470 · ownership.xml · nonDerivative · entry 2 Bredt David · CIK 0002022087 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 404,075 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units, and does not represent a discretionary trade by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.04 to $30.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 16:20 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | GrantCommon Stock | 18,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-002470 · ownership.xml · nonDerivative · entry 1 Bredt David · CIK 0002022087 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 410,642 F1 · price: On December 4, 2024, the Reporting Person was granted performance-based restricted stock units ("PSUs") subject to the satisfaction of specified performance criteria as of December 31, 2025. The issuers Compensation Committee confirmed that the performance criteria had been met, resulting in the vesting of such PSUs effective December 31, 2025. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 17:07 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 796 | $30.68 | $24,419.05 |
DisclosureSEC source: 0001193125-25-321142 · ownership.xml · nonDerivative · entry 2 Bredt David · CIK 0002022087 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 392,642 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.61 to $30.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 17:07 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 7,704 | $29.95 | $230,710.92 |
DisclosureSEC source: 0001193125-25-321142 · ownership.xml · nonDerivative · entry 1 Bredt David · CIK 0002022087 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 393,438 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.58 to $30.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 16:24 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 5,344 | $25.39 | $135,695.92 |
DisclosureSEC source: 0001193125-25-286212 · ownership.xml · nonDerivative · entry 2 Bredt David · CIK 0002022087 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 401,142 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.16 to $25.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 16:24 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 3,156 | $24.84 | $78,394.72 |
DisclosureSEC source: 0001193125-25-286212 · ownership.xml · nonDerivative · entry 1 Bredt David · CIK 0002022087 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 406,486 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.16 to $25.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 16:30 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 1,082 | $26.16 | $28,309.56 |
DisclosureSEC source: 0001193125-25-241475 · ownership.xml · nonDerivative · entry 2 Bredt David · CIK 0002022087 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 409,642 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.07 to $26.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 16:30 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 7,418 | $25.73 | $190,886.65 |
DisclosureSEC source: 0001193125-25-241475 · ownership.xml · nonDerivative · entry 1 Bredt David · CIK 0002022087 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 410,724 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.07 to $26.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 16:15 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 3,402 | $24.66 | $83,887.54 |
DisclosureSEC source: 0001193125-25-206203 · ownership.xml · nonDerivative · entry 2 Bredt David · CIK 0002022087 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 418,142 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.42 to $24.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 16:15 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 5,098 | $23.88 | $121,761.14 |
DisclosureSEC source: 0001193125-25-206203 · ownership.xml · nonDerivative · entry 1 Bredt David · CIK 0002022087 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 421,544 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.42 to $24.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| August 15, 2025 Filed Aug 18, 2025 17:14 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 200 | $15.79 | $3,158.00 |
DisclosureSEC source: 0000950170-25-109838 · ownership.xml · nonDerivative · entry 2 Bredt David · CIK 0002022087 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 426,642 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.74 to $15.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| August 15, 2025 Filed Aug 18, 2025 17:14 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 8,300 | $14.98 | $124,308.27 |
DisclosureSEC source: 0000950170-25-109838 · ownership.xml · nonDerivative · entry 1 Bredt David · CIK 0002022087 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 426,842 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.65 to $15.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| July 15, 2025 Filed Jul 16, 2025 16:14 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 8,500 | $14.00 | $118,961.75 |
DisclosureSEC source: 0000950170-25-096268 · ownership.xml · nonDerivative · entry 1 Bredt David · CIK 0002022087 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 435,142 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.565 to $14.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 16:15 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 8,500 | $11.00 | $93,522.10 |
DisclosureSEC source: 0000950170-25-087897 · ownership.xml · nonDerivative · entry 1 Bredt David · CIK 0002022087 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 443,642 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.67 to $11.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| May 15, 2025 Filed May 19, 2025 16:30 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 8,500 | $9.56 | $81,261.70 |
DisclosureSEC source: 0000950170-25-074409 · ownership.xml · nonDerivative · entry 1 Bredt David · CIK 0002022087 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 452,142 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.19 to $9.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| April 15, 2025 Filed Apr 16, 2025 17:00 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 8,500 | $9.57 | $81,310.15 |
DisclosureSEC source: 0000950170-25-054819 · ownership.xml · nonDerivative · entry 1 Bredt David · CIK 0002022087 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 460,642 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.18 to $10.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| March 14, 2025 Filed Mar 17, 2025 17:00 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 8,500 | $10.85 | $92,205.45 |
DisclosureSEC source: 0000950170-25-040447 · ownership.xml · nonDerivative · entry 1 Bredt David · CIK 0002022087 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 469,142 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.42 to $11.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 17:30 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $16.60 | $0.00 |
DisclosureSEC source: 0000950170-25-013752 · ownership.xml · derivative · entry 1 Bredt David · CIK 0002022087 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-02-03 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 19:43 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | GrantStock Option (Right to Buy) · Derivative | 28,302 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000950170-24-071539 · ownership.xml · derivative · entry 1 Bredt David · CIK 0002022087 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,302 Underlying: Common Stock · 28,302 shares Expires 2034-06-05 F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on June 6, 2025, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.